Post-Doc, Comp Chemistry

Novartis Institutes for BioMedical Research is Novartis' global research organization and is committed to discovering innovative medicines that cure disease and improve human health. By conducting more relevant and predictable drug discovery that can yield new and better medicines for patients, Novartis Institutes for BioMedical Research is redefining drug discovery in the post-genomic era.

Over the past four years, Novartis Pharmaceuticals has had the greatest number of new molecular entities approved by the US FDA. With its broad focus on diseases for which there is a need for better medical therapies, and with over 3,000 talented, dedicated research scientists worldwide, Novartis Institutes for BioMedical Research is well-positioned to ensure Novartis maintains its strong pipeline and highly successful track record in new drug discovery.

Novartis Institutes has sites in Cambridge, Massachusetts (headquarters); Basel, Switzerland; Horsham, UK; East Hanover, NJ; Vienna, Austria; Tsukuba, Japan and Emeryville, California. Novartis Institutes' Cambridge facilities encompass 950,000 square feet of laboratory and office space. Research in cardiovascular disease, oncology, infectious disease, diabetes, ophthalmology and muscle disease is headquartered in Cambridge. In addition, Cambridge is home to the following platform technologies: Global Discovery Chemistry, Functional Genomics, Developmental & Molecular Pathways, and Models of Disease Center.

In order to attract and develop an exceptionally talented and committed staff, Novartis Institutes for BioMedical Research offers an innovative and comprehensive benefits package, including healthcare, insurance, savings, retirement, and work/life benefits. A NIBR Postdoctoral Fellowship position is available for a highly-motivated scientist to join a dynamic group in the Computational Chemistry Group of the Global Discovery Chemistry department. This is an exciting opportunity to perform cutting-edge research in an industry setting at our Emeryville California site. The project will extend the application of the Autoshim methodology for kinase-family 3D docking to lead optimization, cellular activity, other protein families, and difficult homology models. [see AutoShim: Empirically Corrected Scoring Functions for Quantitative Docking with a Crystal Structure and IC50 Training Data, Eric J. Martin and David C. Sullivan, J Chem Inf Modeling ASAP (2008), and Surrogate AutoShim: Predocking into a Universal Ensemble Kinase Receptor for Three Dimensional Activity Prediction, Very Quickly, without a Crystal Structure, Eric J. Martin and David C. Sullivan, J Chem Inf Modeling ASAP (2008).] The fellowship is for a single 3-year term.
Novartis Institutes for BioMedical Research is an equal opportunity employer committed to embracing and leveraging diverse backgrounds. M/F/D/V